HDAC9 and chondrosarcoma: These drugs either have a known synergistic effect with HDAC inhibitors (e.g., chemotherapy and proteasome inhibitors [22]) or were previously successful as single agent in chondrosarcoma cell lines (e.g., PARP and NAMPT inhibitors [23,24]).